7U6Z image
Deposition Date 2022-03-06
Release Date 2022-04-13
Last Version Date 2023-10-18
Entry Detail
PDB ID:
7U6Z
Title:
Pertussis toxin E129D NAD
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.30 Å
R-Value Free:
0.21
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 1 21 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Pertussis toxin subunit 1
Gene (Uniprot):ptxA
Chain IDs:A (auth: B), B (auth: A)
Chain Length:184
Number of Molecules:2
Biological Source:Bordetella pertussis
Primary Citation
Crystal structures of pertussis toxin with NAD + and analogs provide structural insights into the mechanism of its cytosolic ADP-ribosylation activity.
J.Biol.Chem. 298 101892 101892 (2022)
PMID: 35378130 DOI: 10.1016/j.jbc.2022.101892

Abstact

Bordetella pertussis is the causative agent of whooping cough, a highly contagious respiratory disease. Pertussis toxin (PT), a major virulence factor secreted by B. pertussis, is an AB5-type protein complex topologically related to cholera toxin. The PT protein complex is internalized by host cells and follows a retrograde trafficking route to the endoplasmic reticulum, where it subsequently dissociates. The released enzymatic S1 subunit is then translocated from the endoplasmic reticulum into the cytosol and subsequently ADP-ribosylates the inhibitory alpha-subunits (Gαi) of heterotrimeric G proteins, thus promoting dysregulation of G protein-coupled receptor signaling. However, the mechanistic details of the ADP-ribosylation activity of PT are not well understood. Here, we describe crystal structures of the S1 subunit in complex with nicotinamide adenine dinucleotide (NAD+), with NAD+ hydrolysis products ADP-ribose and nicotinamide, with NAD+ analog PJ34, and with a novel NAD+ analog formed upon S1 subunit crystallization with 3-amino benzamide and NAD+, which we name benzamide amino adenine dinucleotide. These crystal structures provide unprecedented insights into pre- and post-NAD+ hydrolysis steps of the ADP-ribosyltransferase activity of PT. We propose that these data may aid in rational drug design approaches and further development of PT-specific small-molecule inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures